Targeting FGFR Signaling in Cancer: Bladder and Beyond

Download All
Get up to date on emerging therapeutic strategies to target FGFR in the treatment of patients with cancer with this expert-authored online activity featuring Podcasts, expert commentaries, and downloadable slides.
Alison Birtle, MD, FRCP, FRCR
person default
Ignacio Duran, MD, PhD

Podcasts

Listen to Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, discuss the most recent clinical data on targeting FGFR in urothelial cancer and other malignancies.

Alison Birtle, MD, FRCP, FRCR person default Ignacio Duran, MD, PhD Released: March 23, 2021

Experts, Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, discuss the most recent clinical data on targeting FGFR in urothelial cancer and beyond.

Alison Birtle, MD, FRCP, FRCR person default Ignacio Duran, MD, PhD Released: April 1, 2021

Listen to Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, discuss their thoughts on what to know about managing toxicities associated with FGFR inhibitors in the treatment of urothelial cancer and other malignancies.

Alison Birtle, MD, FRCP, FRCR person default Ignacio Duran, MD, PhD Released: May 4, 2021

Experts, Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, discuss their thoughts on what to know about managing toxicities associated with FGFR inhibitors in the treatment of urothelial cancer and other malignancies.

Alison Birtle, MD, FRCP, FRCR person default Ignacio Duran, MD, PhD Released: May 4, 2021
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Janssen Pharmaceutica NV

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue